The University Of Kansas Medical Center | United States
Author Profiles
Scopus
Orcid ID
Early Academic Pursuits
Dr. Winston Dunn began his academic journey with a Bachelor of Science in Biochemistry from the University of British Columbia. He pursued his medical degree at Ross University School of Medicine and later completed advanced training at The Chicago Medical School. His strong foundation in internal medicine was built through residency at the Mayo Graduate School of Medicine, followed by specialized fellowships in Gastroenterology at the University of California, San Diego, and in Transplant Hepatology at Mayo Clinic. Parallel to his clinical training, he enriched his expertise with a Master’s in Public Health, highlighting his commitment to blending clinical practice with population health perspectives.
Professional Endeavors
Dr. Dunn’s academic career began as an Instructor in Medicine at the Mayo Clinic College of Medicine (2009–2010). He then joined the University of Kansas Medical Center as an Assistant Professor (2010–2016), rising to Associate Professor (2016–2025), and currently serves as Professor in the Division of Gastroenterology. His steady progression reflects consistent excellence in teaching, research, and clinical leadership. Additionally, his professional licensure across multiple states and board certifications in Internal Medicine, Gastroenterology, and Transplant Hepatology highlight his depth of expertise.
Contributions and Research Focus
Dr. Dunn’s research is primarily centered on liver diseases, with a special focus on nonalcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and outcomes after hepatitis C treatment. He has been the principal investigator in numerous Phase II and Phase III clinical trials, collaborating with leading pharmaceutical companies and institutions. His studies explore genetic predictors of liver disease outcomes, non-invasive biomarkers, and novel therapeutics aimed at reversing fibrosis and improving survival. He also contributed to improving models of care, diagnosis, and patient referral systems in hepatology.
Impact and Influence
Dr. Dunn’s work has had significant clinical implications, advancing knowledge in liver transplantation, NASH therapeutics, and hepatology practice. His role in high-impact trials, including those supported by Gilead Sciences, Novo Nordisk, and Madrigal Pharmaceuticals, positions him as a leader in shaping the future of liver disease management. His active service on the AASLD Alcoholic Liver Disease Steering Committee and Education Subcommittee further demonstrates his influence on clinical guidelines, education, and policy within the hepatology community.
Academic Citations and Recognition
Dr. Dunn’s contributions have been recognized through multiple awards, including the Sheila Sherlock Clinical and Translational Research Award (2012), the AASLD Advanced Transplant Hepatology Fellowship Award (2009), and induction as a Fellow of the American Association for the Study of Liver Diseases (FAASLD) in 2023. His research has generated numerous publications and citations, reflecting his impact on both scientific literature and clinical practice.
Legacy and Future Contributions
With an established record of academic excellence, groundbreaking research, and mentorship, Dr. Dunn’s legacy lies in advancing hepatology through both innovative research and translational impact. His ongoing leadership in pivotal trials will likely redefine therapeutic standards for NASH and related liver conditions. As a Professor at the University of Kansas Medical Center, he is poised to continue mentoring future hepatologists while contributing to international collaborations that influence the global fight against liver disease.
Conclusion
In summary, Dr. Winston Dunn exemplifies the qualities of a distinguished academic physician-scientist. His rigorous training, progressive academic career, and pioneering research in hepatology underscore his suitability for honors such as the Best Researcher Award. With a career dedicated to bridging clinical care, research innovation, and education, Dr. Dunn stands as a role model whose work continues to shape the future of liver disease management and patient outcomes worldwide.
Notable Publications
“Artificial Intelligence for Predictive Diagnostics, Prognosis, and Decision Support in MASLD, Hepatocellular Carcinoma, and Digital Pathology"
- Author: Nicholas Dunn; Nipun Verma; Winston Dunn
- Journal: Journal of Clinical and Experimental Hepatology
- Year: 2025
"Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States"
- Author: Sheila L. Noon; Lauren F. Chun; Tin Bo Nicholas Lam; Nhat Quang N. Thai; Winston Dunn; Jeffrey B. Schwimmer
- Journal: Alimentary Pharmacology & Therapeutics
- Year: 2025
"Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study"
- Author: Francisco Idalsoaga; Luis Antonio Díaz; Leonardo Guizzetti; Winston Dunn; Heer Mehta; Jorge Arnold; Gustavo Ayares; Rokhsana Mortuza; Gurpreet Mahli; Alvi H. Islam et al.
- Journal: Alimentary Pharmacology & Therapeutics
- Year: 2025
"Moderate alcohol-associated hepatitis: A real-world multicenter study"
- Author: Francisco Idalsoaga; Luis Antonio Díaz; Winston Dunn; Heer Mehta; Karen Muñoz; Vicente Caldentey; Jorge Arnold; Gustavo Ayares; Rokhsana Mortuza; Shiv K. Sarin et al.
- Journal: Hepatology Communications
- Year: 2025
"An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study"
- Author: Winston Dunn; Yanming Li; Ashwani K. Singal; Douglas A. Simonetto; Luis A. Díaz; Francisco Idalsoaga; Gustavo Ayares; Jorge Arnold; María Ayala-Valverde; Diego Perez et al.
- Journal: Hepatology
- Year: 2024